YBGJ (Yubo International Biotech) Beta: 3.4301 (As of Jun. 27, 2026)


What is Yubo International Biotech Beta?

Yubo International Biotech YBGJ +30.43% Beta is 3.4301 as of Jun. 27, 2026. The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), Yubo International Biotech's Beta is 3.4301.

Yubo International Biotech  (OTCPK:YBGJ) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Yubo International Biotech Beta Related Terms

Yubo International Biotech Beta Historical Data

* Premium members only.

The historical data trend for Yubo International Biotech's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yubo International Biotech Beta Chart

Yubo International Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 2.58 5.20

Yubo International Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.62 2.79 4.31 5.20 5.13

YBGJ vs ECIA, GCTK, RSCF: Beta Comparison

For the Medical Instruments & Supplies subindustry, Yubo International Biotech's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yubo International Biotech Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Yubo International Biotech's Beta distribution charts can be found below:

* The bar in red indicates where Yubo International Biotech's Beta falls into.


Yubo International Biotech Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 3.4301 mean?
Yubo International Biotech (YBGJ) has a Beta of 3.4301 as of Jun. 27, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Yubo International Biotech and its competitors.
Is Yubo International Biotech's Beta too high?
Yubo International Biotech's current Beta is 3.4301.
How does Yubo International Biotech's Beta compare to ECIA and GCTK?
Yubo International Biotech's Beta of 3.4301 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Yubo International Biotech and its competitors. Yubo International Biotech's current Beta is 3.4301. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yubo International Biotech stock overvalued right now?
Yubo International Biotech (YBGJ) has a current Beta of 3.4301. The current Beta is 3.4301. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Yubo International Biotech (YBGJ), the current Beta is 3.4301 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Yubo International Biotech Business Description

Address No. 10 Chaoyang Park South Road, Room 1102, 11th Floor, Building 2, Chaoyang District, Beijing, CHN, 100026
Yubo International Biotech Ltd is a technology company focused on the research, development, and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of certain health management services and the sale of nebulizers containing frozen tubes with medical fluid. The nebulizers are sold directly to consumers on its online e-commerce platform.